Bushu and Suzuken team up to support manufacturers eyeing up Japanese market
The new business alliance will support new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market
Contract manufacturer Bushu Pharmaceuticals has signed a business agreement with Suzuken, to offer support services for new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market.
The alliance between the two firms will establish a one-stop logistics centre in Soka City, Saitama Prefecture, for manufacturing operations and general logistics.
Bushu Pharma will be able to conduct contract manufacturing operations from the site and the two companies will work together to offer one-stop services for specialty pharmaceuticals, including marketing authorisation holder/drug approval holder consulting, import, inspection, manufacturing, storage (manufacturer logistics), wholesale distribution, post-marketing survey, and patient support.
In addition, through the use of the Cubixx specialty drug traceability system, developed by Suzuken, Bushu Pharma will provide delivery of products all the way to patients.
The alliance also enables Bushu Pharma to utilize the 1,465-m2 cold storage area newly established within the Kazo Pharmaceutical Joint Distribution Center of Chuo Unyu, a subsidiary of Suzuken. The area will make it possible for Bushu Pharma to carry out contract manufacturing centered on secondary packaging such as inspection, labelling, and packaging.
Furthermore, the two companies, including S.D. Collaboration Co. (another Suzuken subsidiary), have also started joint proposal sales efforts to specialty pharmaceutical manufacturers who are planning to enter the Japanese market, led through Bushu Pharma’s US office in North Carolina.
In recent years, the number of innovative specialty pharmaceuticals on the market that require strict temperature, inventory, and security control has been increasing, as has the number of pharmaceutical manufacturers looking to introduce these products to Japan. These manufacturers, however, frequently lack the required assets such as manufacturing plants, distribution centres and networks necessary to enter the Japanese market with minimal resources and, therefore, must outsource these functions.
Suzuken possesses a distribution network in Japan that can support the international transportation of specialty pharmaceuticals. Bushu Pharma has been contract manufacturing in Japan for more than 20 years, holds GMP certifications from all over the world, and has a track record of exporting to more than 43 countries.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance